Insider Trading Arrangements

3 Months Ended

Sep. 30, 2025

Trading Plans or Rule 10b5-1 Trading Plans

During the quarter ended September 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.



Name	Position	Action	Date of Adoption/ Termination	Type of Trading Arrangement		Expiration Date	Total Shares of Common Stock to be Sold***
Name	Position	Action	Date of Adoption/ Termination	Rule 10b5-1*	Non-Rule 10b5-1**	Expiration Date	Total Shares of Common Stock to be Sold***
Shane Kovacs	Chief Operating and Financial Officer	Adoption(1)	February 3, 2025		X(2)	May 12, 2026	Up to 150,000
Shane Kovacs	Chief Operating and Financial Officer	Termination(3)	September 10, 2025(4)		X	May 12, 2026	Up to 150,000

* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

** "Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.

*** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 trading arrangement. The number of shares to be sold was dependent on the satisfaction of certain conditions as set forth in the written plan.

(1) We inadvertently omitted from Item 5 of Part II of our Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2025, the disclosure of the adoption of a contract, instruction or written plan for the purchase or sale of our securities.

(2) This plan was intended to qualify as a “Rule 10b5-1 trading arrangement” as defined in Item 408(a) of Regulation S-K. However, the plan did not comply with the cooling-off period required by Exchange Act Rule 10b5-1(c) and is therefore deemed a “Non-Rule 10b5-1 trading arrangement”.

(3) This contract, instruction, or written plan was subsequently terminated on September 10, 2025, as disclosed above, prior to the completion of any sales under the plan.

(4) Represents the termination of a written plan originally adopted on February 3, 2025 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Name

Shane Kovacs

Title

Chief Operating and Financial Officer

Non-Rule 10b5-1 Arrangement Terminated

true

September 10, 2025

May 12, 2026

464 days

150,000

Olema Pharmaceuticals, Inc. 10-Q